Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis

Next Previous
Trial Profile

An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie

    • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 15 Oct 2022 to 23 Feb 2024.
    • 18 Dec 2018 Planned primary completion date changed from 28 Aug 2020 to 29 Dec 2021.
    • 18 Dec 2018 Planned initiation date changed from 23 Aug 2018 to 27 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top